Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 7 (July)

1. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk?
   Fertil Steril, 90(1): 129-40. [Abstract] [Full-text]
2. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients.
   Fertil Steril, 90(1): 17-22. [Abstract] [Full-text]
3. True incidence of all complications following immediate and delayed breast reconstruction.
   Plast Reconstr Surg, 122(1): 19-28. [Abstract] [Full-text]
4. Prophylactic mastectomy and reconstruction: clinical outcomes and patient satisfaction.
   Plast Reconstr Surg, 122(1): 1-9. [Abstract] [Full-text]
5. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy.
   Clin Cancer Res, 14(13): 4259-66. [Abstract] [Full-text]
6. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
   Clin Cancer Res, 14(13): 4241-9. [Abstract] [Full-text]
7. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
   Clin Cancer Res, 14(13): 4200-5. [Abstract] [Full-text]
8. Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort.
   Clin Cancer Res, 14(13): 4168-74. [Abstract] [Full-text]
9. Molecular subtypes of breast cancers detected in mammography screening and outside of screening.
   Clin Cancer Res, 14(13): 4103-10. [Abstract] [Full-text]
10. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast.
    Clin Cancer Res, 14(13): 4038-44. [Abstract] [Full-text]
11. Multiple loci with different cancer specificities within the 8q24 gene desert.
    J Natl Cancer Inst, 100(13): 962-6. [Abstract] [Full-text]
12. Association of size at birth with adolescent hormone levels, body size and age at menarche: relevance for breast cancer risk.
    Br J Cancer, 99(1): 201-6. [Abstract] [Full-text]
13. Soy intake and breast cancer risk in Singapore Chinese Health Study.
    Br J Cancer, 99(1): 196-200. [Abstract] [Full-text]
14. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda.
    Br J Cancer, 99(1): 63-7. [Abstract] [Full-text]
15. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers.
    Br J Cancer, 99(1): 68-71. [Abstract] [Full-text]
16. Anthropometric factors and breast cancer risk among urban and rural women in South India: a multicentric case-control study.
    Br J Cancer, 99(1): 207-13. [Abstract] [Full-text]
17. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
    Oncogene, 27(29): 4086-95. [Abstract] [Full-text]
18. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.
    Oncogene, 27(29): 4075-85. [Abstract] [Full-text]
19. Intraoperative frozen section assessment of sentinel lymph nodes in the operative management of women with symptomatic breast cancer.
    World J Surg Oncol, 6: 69. [Abstract] [Full-text]
20. Multielemental determination in breast cancerous and non-cancerous biopsies by inductively coupled plasma-mass spectrometry following small volume microwave-assisted digestion.
    Anal Chim Acta, 622(1): 77-84. [Abstract] [Full-text]
21. Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
    J Med Chem, 51(13): 3895-904. [Abstract] [Full-text]
22. Selective blockade of T-type Ca2+ channels suppresses human breast cancer cell proliferation.
    Cancer Lett, 267(1): 116-24. [Abstract] [Full-text]
23. Cell cycle regulated phosphorylation of LIMD1 in cell lines and expression in human breast cancers.
    Cancer Lett, 267(1): 55-66. [Abstract] [Full-text]
24. Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells.
    Cancer Lett, 267(1): 75-84. [Abstract] [Full-text]
25. Hereditary breast cancer: new genetic developments, new therapeutic avenues.
    Hum Genet, 124(1): 31-42. [Abstract] [Full-text]
26. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer.
    Brain Behav Immun, 22(6): 969-81. [Abstract] [Full-text]
27. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    J Clin Oncol, 26(20): 3426-33. [Abstract] [Full-text]
28. Disclosure of incurable illness to spouses: do they want to know? A Swedish population-based follow-up study.
    J Clin Oncol, 26(20): 3372-9. [Abstract] [Full-text]
29. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer.
    J Clin Oncol, 26(20): 3338-45. [Abstract] [Full-text]
30. Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life.
    J Clin Oncol, 26(20): 3331-7. [Abstract] [Full-text]
31. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
    J Clin Oncol, 26(20): 3324-30. [Abstract] [Full-text]
32. Risk factors for the incidence of breast cancer: do they affect survival from the disease?
    J Clin Oncol, 26(20): 3310-6. [Abstract] [Full-text]
33. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
    J Clin Oncol, 26(20): 3317-23. [Abstract] [Full-text]
34. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.
    Oncogene, 27(30): 4233-41. [Abstract] [Full-text]
35. Clinical significance of preoperative lymphoscintigraphy for sentinel lymph node biopsy in breast cancer.
    J Surg Res, 148(2): 191-6. [Abstract] [Full-text]
36. Breast cancer during pregnancy: a mini-review.
    Eur J Surg Oncol, 34(8): 837-43. [Abstract] [Full-text]
37. Breast conserving surgery after neoadjuvant therapy for large primary breast cancer.
    Eur J Surg Oncol, 34(8): 863-7. [Abstract] [Full-text]
38. Lymphatic mapping in patients with primary or recurrent breast cancer following previous axillary surgery.
    Eur J Surg Oncol, 34(8): 851-6. [Abstract] [Full-text]
39. The location of small tumor deposits in the SLN predicts Non-SLN macrometastases in breast cancer patients.
    Eur J Surg Oncol, 34(8): 857-62. [Abstract] [Full-text]
40. Use of glycan targeting antibodies to identify cancer-associated glycoproteins in plasma of breast cancer patients.
    Anal Chem, 80(14): 5286-92. [Abstract] [Full-text]
41. Nitrophenols isolated from diesel exhaust particles promote the growth of MCF-7 breast adenocarcinoma cells.
    Toxicol Appl Pharmacol, 230(3): 320-6. [Abstract] [Full-text]
42. Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta.
    Steroids, 73(11): 1077-89. [Abstract] [Full-text]
43. ERbeta in breast cancer--onlooker, passive player, or active protector?
    Steroids, 73(11): 1039-51. [Abstract] [Full-text]
44. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype.
    Br J Cancer, 99(2): 327-34. [Abstract] [Full-text]
45. Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer.
    Br J Cancer, 99(2): 335-40. [Abstract] [Full-text]
46. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk.
    J Natl Cancer Inst, 100(14): 1037-41. [Abstract] [Full-text]
47. Secular trends in mortality from common cancers in the United States by educational attainment, 1993-2001.
    J Natl Cancer Inst, 100(14): 1003-12. [Abstract] [Full-text]
48. Distinct lymph nodal sonographic characteristics in breast cancer patients at high risk for axillary metastases correlate with the final axillary stage.
    Br J Radiol, 81(968): 630-6. [Abstract] [Full-text]
49. Frequency and clinical significance of simultaneous association of lobular neoplasia and columnar cell alterations in breast tissue specimens.
    Am J Clin Pathol, 130(2): 254-8. [Abstract] [Full-text]
50. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers.
    Breast Cancer Res Treat, 111(1): 113-20. [Abstract] [Full-text]
51. Identification of the functional role of AF1Q in the progression of breast cancer.
    Breast Cancer Res Treat, 111(1): 65-78. [Abstract] [Full-text]
52. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast.
    Breast Cancer Res Treat, 111(1): 121-7. [Abstract] [Full-text]
53. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer.
    Breast Cancer Res Treat, 111(1): 93-101. [Abstract] [Full-text]
54. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.
    Breast Cancer Res Treat, 111(1): 27-44. [Abstract] [Full-text]
55. The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer.
    Breast Cancer Res Treat, 111(1): 171-7. [Abstract] [Full-text]
56. Influence of preoperative MRI on the surgical management of patients with operable breast cancer.
    Breast Cancer Res Treat, 111(1): 179-87. [Abstract] [Full-text]
57. Old masters as clinical photographers: multifocal breast cancer diagnosed 400 years ago.
    Breast Cancer Res Treat, 111(1): 11-3. [Abstract] [Full-text]
58. Current management of DCIS: a review.
    Breast Cancer Res Treat, 111(1): 1-10. [Abstract] [Full-text]
59. MAZ drives tumor-specific expression of PPAR gamma 1 in breast cancer cells.
    Breast Cancer Res Treat, 111(1): 103-11. [Abstract] [Full-text]
60. A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer.
    Breast Cancer Res Treat, 111(1): 55-63. [Abstract] [Full-text]
61. Modification of risk for subsequent cancer after female breast cancer by a family history of breast cancer.
    Breast Cancer Res Treat, 111(1): 165-9. [Abstract] [Full-text]
62. Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan.
    Breast Cancer Res Treat, 111(1): 145-55. [Abstract] [Full-text]
63. Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer.
    Breast Cancer Res Treat, 111(1): 45-53. [Abstract] [Full-text]
64. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study.
    Breast Cancer Res Treat, 111(1): 139-44. [Abstract] [Full-text]
65. Association of polymorphisms of angiogenesis genes with breast cancer.
    Breast Cancer Res Treat, 111(1): 157-63. [Abstract] [Full-text]
66. Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR.
    Breast Cancer Res Treat, 111(1): 15-25. [Abstract] [Full-text]
67. Linkage disequilibrium mapping of a breast cancer susceptibility locus near RAI/PPP1R13L/iASPP.
    BMC Med Genet, 9: 56. [Abstract] [Full-text]
68. Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice.
    Oncogene, 27(31): 4305-14. [Abstract] [Full-text]
69. Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms.
    Cancer Res, 68(14): 5997-6005. [Abstract] [Full-text]
70. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Cancer Res, 68(14): 5878-87. [Abstract] [Full-text]
71. Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients.
    Cancer Res, 68(14): 5869-77. [Abstract] [Full-text]
72. Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells.
    Cancer Res, 68(14): 5678-88. [Abstract] [Full-text]
73. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas.
    Cancer Res, 68(14): 5562-71. [Abstract] [Full-text]
74. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
    Cancer Res, 68(14): 5533-9. [Abstract] [Full-text]
75. Monitoring serial changes in circulating human breast cancer cells in murine xenograft models.
    Cancer Res, 68(14): 5529-32. [Abstract] [Full-text]
76. Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding.
    Mol Cell Biol, 28(15): 4896-914. [Abstract] [Full-text]
77. The feasibility of patient-controlled paravertebral analgesia for major breast cancer surgery: a prospective, randomized, double-blind comparison of two regimens.
    Anesth Analg, 107(2): 665-8. [Abstract] [Full-text]
78. Effect of lesion morphology on microwave signature in 2-D ultra-wideband breast imaging.
    IEEE Trans Biomed Eng, 55(8): 2011-21. [Abstract] [Full-text]
79. Two-dimensional time-domain inverse scattering for quantitative analysis of breast composition.
    IEEE Trans Biomed Eng, 55(8): 1941-5. [Abstract] [Full-text]
80. US-guided 14-gauge core-needle breast biopsy: results of a validation study in 1352 cases.
    Radiology, 248(2): 406-13. [Abstract] [Full-text]
81. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures.
    J Clin Oncol, 26(21): 3631-7. [Abstract] [Full-text]
82. Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function.
    J Clin Oncol, 26(21): 3536-42. [Abstract] [Full-text]
83. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011.
    J Clin Oncol, 26(21): 3530-5. [Abstract] [Full-text]
84. Breast US computer-aided diagnosis workstation: performance with a large clinical diagnostic population.
    Radiology, 248(2): 392-7. [Abstract] [Full-text]
85. Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions.
    Radiology, 248(2): 398-405. [Abstract] [Full-text]
86. Surgeon-performed ultrasound reliably predicts skin spacing and may decrease the rate of MammoSite balloon catheter explantation in patients undergoing brachytherapy for breast cancer.
    Am J Surg, 196(2): 289-92. [Abstract] [Full-text]
87. Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer.
    Am J Surg, 196(2): 228-33. [Abstract] [Full-text]
88. Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose.
    Mol Carcinog, 47(8): 616-28. [Abstract] [Full-text]
89. Nitric oxide, N omega-hydroxy-L-arginine and breast cancer.
    Nitric Oxide, 19(2): 103-6. [Abstract] [Full-text]
90. Novel de novo BRCA2 mutation in a patient with a family history of breast cancer.
    BMC Med Genet, 9: 58. [Abstract] [Full-text]
91. Decreased breast cancer rates among women with choriocarcinoma.
    Gynecol Oncol, 110(2): 202-5. [Abstract] [Full-text]
92. Breast carcinoma with basal phenotype: mammographic findings.
    AJR Am J Roentgenol, 191(2): 346-51. [Abstract] [Full-text]
93. National trends and practices in breast MRI.
    AJR Am J Roentgenol, 191(2): 332-9. [Abstract] [Full-text]
94. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells.
    Endocrinology, 149(8): 3799-808. [Abstract] [Full-text]
95. Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites.
    Int J Cancer, 123(6): 1466-71. [Abstract] [Full-text]
96. Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.
    Int J Cancer, 123(6): 1433-8. [Abstract] [Full-text]
97. Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues.
    Int J Cancer, 123(6): 1327-38. [Abstract] [Full-text]
98. The effect of dedicated breast surgeons on the short-term outcomes in breast cancer.
    Ann Surg, 248(2): 280-5. [Abstract] [Full-text]
99. Are many community hospitals undertreating breast cancer?: lessons from 24,834 patients.
    Ann Surg, 248(2): 154-62. [Abstract] [Full-text]
100. Activated c-Abl tyrosine kinase in malignant solid tumors.
     Oncogene, 27(32): 4385-91. [Abstract] [Full-text]
101. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion.
     Oncogene, 27(32): 4434-45. [Abstract] [Full-text]
102. Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression.
     Exp Cell Res, 314(13): 2448-53. [Abstract] [Full-text]
103. Three-dimensional digital evaluation of breast symmetry after breast conservation therapy.
     J Am Coll Surg, 207(2): 227-32. [Abstract] [Full-text]
104. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer.
     Hum Pathol, 39(8): 1221-8. [Abstract] [Full-text]
105. The E75 HER2/neu peptide vaccine.
     Cancer Immunol Immunother, 57(10): 1511-21. [Abstract] [Full-text]
106. Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis.
     Cancer Immunol Immunother, 57(10): 1471-81. [Abstract] [Full-text]
107. Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells.
     J Cell Biol, 182(2): 327-40. [Abstract] [Full-text]
108. Fine needle aspiration cytology of papillary lesions of the breast: how accurate is the diagnosis?
     J Clin Pathol, 61(8): 945-9. [Abstract] [Full-text]
109. Large volume "mammotome" biopsy may reduce the need for diagnostic surgery in papillary lesions of the breast.
     J Clin Pathol, 61(8): 928-33. [Abstract] [Full-text]
110. Feedback regulation between zipcode binding protein 1 and beta-catenin mRNAs in breast cancer cells.
     Mol Cell Biol, 28(16): 4963-74. [Abstract] [Full-text]
111. Targeting Src in breast cancer.
     Ann Oncol, 19(8): 1379-86. [Abstract] [Full-text]
112. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
     J Clin Pathol, 61(8): 934-8. [Abstract] [Full-text]
113. Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy.
     Ann Oncol, 19(8): 1402-6. [Abstract] [Full-text]
114. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
     Ann Oncol, 19(8): 1417-22. [Abstract] [Full-text]
115. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.
     Ann Oncol, 19(8): 1423-9. [Abstract] [Full-text]
116. Satisfaction with and psychological impact of immediate and deferred breast reconstruction.
     Ann Oncol, 19(8): 1430-4. [Abstract] [Full-text]
117. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer.
     Ann Oncol, 19(8): 1393-401. [Abstract] [Full-text]
118. Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells.
     J Cell Physiol, 217(1): 172-83. [Abstract] [Full-text]
119. Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors.
     Appl Radiat Isot, 66(9): 1175-82. [Abstract] [Full-text]
120. Cell cycle dysregulation influences survival in high risk breast cancer patients.
     Cancer Invest, 26(7): 734-40. [Abstract] [Full-text]
121. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
     Cancer Invest, 26(7): 671-9. [Abstract] [Full-text]
122. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress.
     Cancer Invest, 26(7): 698-707. [Abstract] [Full-text]
123. Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs.
     Cancer Invest, 26(7): 662-70. [Abstract] [Full-text]
124. Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature.
     Am J Surg Pathol, 32(8): 1265-8. [Abstract] [Full-text]
125. Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer.
     Br J Cancer, 99(3): 513-9. [Abstract] [Full-text]
126. Effectiveness of service screening: a case-control study to assess breast cancer mortality reduction.
     Br J Cancer, 99(3): 423-7. [Abstract] [Full-text]
127. Implementing a system of quality-of-life diagnosis and therapy for breast cancer patients: results of an exploratory trial as a prerequisite for a subsequent RCT.
     Br J Cancer, 99(3): 415-22. [Abstract] [Full-text]
128. Selecting high priority quality measures for breast cancer quality improvement.
     Med Care, 46(8): 762-70. [Abstract] [Full-text]
129. PRAME expression and clinical outcome of breast cancer.
     Br J Cancer, 99(3): 398-403. [Abstract] [Full-text]
130. Human papillomavirus detected in female breast carcinomas in Japan.
     Br J Cancer, 99(3): 408-14. [Abstract] [Full-text]
131. High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study.
     Br J Cancer, 99(3): 404-7. [Abstract] [Full-text]
132. Second breast cancers in a Tuscan case series: characteristics, prognosis, and predictors of survival.
     Br J Cancer, 99(3): 539-44. [Abstract] [Full-text]
133. Multiple pathways are involved in the anoxia response of SKIP3 including HuR-regulated RNA stability, NF-kappaB and ATF4.
     Oncogene, 27(33): 4532-43. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.